NCI Cancer Bulletin: A Trusted Source for Cancer Research NewsNCI Cancer Bulletin: A Trusted Source for Cancer Research News
June 29, 2004 • Volume 1 / Number 26 E-Mail This Document  |  Download PDF  |  Bulletin Archive/Search  |  Subscribe

The information and links on this page are no longer being updated and are provided for reference purposes only.

Featured Clinical TrialFeatured Clinical Trial

Study of Cancer Susceptibility Among Patients with Inherited Bone Marrow Failure Syndromes (IBMFS)

Name of the Trial
Genetic and Etiology Study of Cancer Susceptibility in Patients and Their Families With Fanconi's Anemia or Other Inherited Disorders of the Bone Marrow (NCI-02-C-0052). See the protocol summary at

Dr. Blanche Alter Principal Investigator
Dr. Blanche Alter of NCI's Division of Cancer Epidemiology and Genetics

Why Is This Trial Important?
Inherited bone marrow failure syndromes (IBMFS) are rare disorders in which the bone marrow fails to adequately produce blood cells. Persons with these syndromes tend to have a very high risk of developing acute leukemia or certain solid tumors, such as head and neck, vulvar, and cervical tumors.

NCI scientists are assembling a study population that includes IBMFS patients and their family members. Researchers want to determine the number of existing cases of cancer in this population, which specific types of cancers are associated with each type of IBMFS, and at what rate IBMFS patients develop cancer. They also hope to identify specific genetic mutations associated with each IBMFS and relate these mutations to cancer risk.

"We hope to help those individuals who have these syndromes by targeting cancer screening/surveillance programs, by avoiding potential carcinogenic exposures such as tobacco, and by avoiding modes of cancer therapy that might be toxic, such as radiation and some forms of chemotherapy," said Dr. Alter.

Who Can Join This Trial?
Researchers seek to enroll up to 1,000 participants (patients and family members) in families with a suspected or proven diagnosis of an IBMFS. See the full list of eligibility criteria for this trial at

Where Is This Trial Taking Place?
This study is taking place at the National Institutes of Health Warren G. Magnuson Clinical Center in Bethesda, Md.

Who to Contact
For more information, visit the study's Web site at or call the NCI Clinical Studies Support Center (CSSC) at 1-888-NCI-1937. CSSC provides information about cancer trials taking place on the NIH campus. The call is toll free and confidential.

An archive of "Featured Clinical Trial" columns is available at